Kestra Medical Technologies, Ltd. (KMTS)

KMTS is growing fast (FY2026 revenue $95.1m, +59% YoY; gross margin 51.4%), but still posts large losses (FY2026 net loss $131.6m) and burns cash (FY2026 operating cash outflow $81.7m plus $34.9m capex). Liquidity is strong (cash & investments $262.2m; current ratio ~4.4) and SEC filings indicate at least a 12-month runway, yet reimbursement/regulatory risks and material internal-control weaknesses remain. Valuation looks rich for a cash-burning business (EV/Sales ~11x; negative free-cash-flow yield), so fundamentalScore = 2 (Do Nothing / watchlist).

Recent FY2026 results + FY2027 revenue guidance and the up-to-$200M non-dilutive financing facility (both announced 2026-07-14) are the dominant short-term drivers; last ~14d media tone is bullish and appears stronger than the prior 30–90d baseline (baseline inferred from aggregator coverage due to sparse primary-tier baseline). Red-Flag Screen clean, but retail/Reddit signal is minimal and legal tooling had access/extraction gaps, keeping conviction moderate.

Score 2/5: KMTS is liquid and short-term oversold, but the late-June/early-July breakout has unraveled. Price is below the SMA20, SMA200, daily VWAP, and all fast moving averages, while MACD remains above zero but below its signal with a negative histogram; ADX near 40 says the active move still has downside trend strength.